tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ATHE Stock Latest News

Alterity Therapeutics reports cash balance of A$40.66M as of June 30
The FlyAlterity Therapeutics reports cash balance of A$40.66M as of June 30
14d ago
ATHE
Buy Rating for Alterity Therapeutics: Promising Phase 2 Results and Investment Opportunity Amid Stock Price Dip
PremiumRatings
Buy Rating for Alterity Therapeutics: Promising Phase 2 Results and Investment Opportunity Amid Stock Price Dip
15d ago
ATHE
Alterity Therapeutics reports topline data from open-label Phase 2 ATH434 trial
PremiumThe Fly
Alterity Therapeutics reports topline data from open-label Phase 2 ATH434 trial
16d ago
ATHE
Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study
PremiumThe Fly
Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study
20d ago
ATHE
Alterity Therapeutics Announces Change in Substantial Holding
PremiumCompany Announcements
Alterity Therapeutics Announces Change in Substantial Holding
1M ago
6K
ATHE
Alterity Therapeutics Announces Cessation of Securities Due to Unmet Conditions
PremiumCompany AnnouncementsAlterity Therapeutics Announces Cessation of Securities Due to Unmet Conditions
1M ago
6K
ATHE
Alterity Therapeutics has several presentations featured at 2025 MSA Congress
Premium
The Fly
Alterity Therapeutics has several presentations featured at 2025 MSA Congress
3M ago
ATHE
Alterity Therapeutics has several presentations featured at 2025 MSA Congress
Premium
The Fly
Alterity Therapeutics has several presentations featured at 2025 MSA Congress
3M ago
ATHE
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
MRK
ATHE
Alterity Therapeutics management to meet with Maxim
PremiumThe Fly
Alterity Therapeutics management to meet with Maxim
3M ago
ATHE
Alterity Therapeutics granted U.S. FDA Fast Track designation for ATH434
PremiumThe Fly
Alterity Therapeutics granted U.S. FDA Fast Track designation for ATH434
3M ago
ATHE
Alterity Therapeutics Reports Positive Phase 2 Trial Results for MSA Treatment
PremiumCompany Announcements
Alterity Therapeutics Reports Positive Phase 2 Trial Results for MSA Treatment
4M ago
6K
ATHE
Alterity Therapeutics reports cash balance of A$17.96M as of March 31
PremiumThe FlyAlterity Therapeutics reports cash balance of A$17.96M as of March 31
4M ago
ATHE
Alterity Therapeutics Announces Director Securities Changes
Premium
Company Announcements
Alterity Therapeutics Announces Director Securities Changes
4M ago
6K
ATHE
Alterity presents ATH434-201 Phase 2 trial results at MSA Symposium
Premium
The Fly
Alterity presents ATH434-201 Phase 2 trial results at MSA Symposium
4M ago
ATHE
Promising Phase 2 Results and Technological Integration Justify Buy Rating for Alterity Therapeutics
PremiumRatings
Promising Phase 2 Results and Technological Integration Justify Buy Rating for Alterity Therapeutics
4M ago
ATHE
Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting
PremiumThe Fly
Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting
4M ago
ATHE
Alterity Therapeutics completes last patient visit in ATH434-202 Phase 2 trial
PremiumThe Fly
Alterity Therapeutics completes last patient visit in ATH434-202 Phase 2 trial
5M ago
ATHE
Alterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment
PremiumCompany Announcements
Alterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment
5M ago
6K
ATHE
Alterity Therapeutics Reports Progress and Financial Results
PremiumCompany AnnouncementsAlterity Therapeutics Reports Progress and Financial Results
5M ago
ATHE
Buy Rating for Alterity Therapeutics: Strong Financial Position and Promising Clinical Results
Premium
Ratings
Buy Rating for Alterity Therapeutics: Strong Financial Position and Promising Clinical Results
5M ago
ATHE
Alterity Therapeutics Announces Change in Substantial Holding
Premium
Company Announcements
Alterity Therapeutics Announces Change in Substantial Holding
6M ago
6K
ATHE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >